SAN DIEGO , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the Company’s management team will present at the following upcoming investor conferences in October: Cantor Global Healthcare Conference Date: Monday, October 1, 2018 Time: 4:40 p.m.
SAN DIEGO , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the pricing of its offering of $240 million aggregate principal amount of 2.50% convertible senior notes due 2025 (the “notes”) to be sold in an underwritten offering.
SAN DIEGO , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced its intention to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in an underwritten offering.
SAN DIEGO , July 30, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Noah L. Rosenberg , M.D., as chief medical officer, where he will oversee the clinical development of Retrophin’s product pipeline. Dr. Rosenberg brings to Retrophin more than 20 years of
Patients continue to enroll in Phase 3 FORT Study of fosmetpantotenate in PKAN and Phase 3 DUPLEX Study of sparsentan in FSGS Phase 2 proof-of-concept study of CNSA-001 in patients with PKU set to initiate; top-line results expected in early 2019 Retrophin Chief Executive Officer Stephen Aselage
SAN DIEGO , July 12, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report second quarter 2018 financial results on Thursday, July 26, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
SAN DIEGO , June 14, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent covering the Company’s product candidate sparsentan which, in addition to being in Phase 3 clinical development for the
Independent Data Monitoring Committee’s (DMC) review of available safety data supports continuing with study as planned; FORT Study now open to pediatric patients aged 6 to 17 Top-line data anticipated in the second half of 2019 SAN DIEGO , June 04, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc.
SAN DIEGO , May 24, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the Company’s management team will present at the following upcoming investor conferences in June: Jefferies 2018 Global Healthcare Conference Date: Thursday, June 7, 2018 Time: 9:00 a.m.
Peter Barron Stark Companies honors Retrophin for its continued commitment to workplace and cultural excellence SAN DIEGO , May 23, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that it has been awarded the Peter Barron Stark Companies ( PBS ) Award for Workplace Excellence
